166 related articles for article (PubMed ID: 20109727)
21. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
22. Clinical aspects of uterine papillary serous carcinoma.
Hamilton CA; Kapp DS; Chan JK
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):26-33. PubMed ID: 18197002
[TBL] [Abstract][Full Text] [Related]
23. Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.
Desai NB; Kollmeier MA; Makker V; Levine DA; Abu-Rustum NR; Alektiar KM
Gynecol Oncol; 2014 Oct; 135(1):49-53. PubMed ID: 25084509
[TBL] [Abstract][Full Text] [Related]
24. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy for patients with stage I papillary serous endometrial cancer.
Alobaid A; Bruchim I; Verkooijen H; Gauthier P; Petignat P
Eur J Surg Oncol; 2006 Apr; 32(3):358-62. PubMed ID: 16414233
[TBL] [Abstract][Full Text] [Related]
26. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Sagae S; Susumu N; Viswanathan AN; Aoki D; Backes FJ; Provencher DM; Vaughan M; Creutzberg CL; Kurzeder C; Kristensen G; Lee C; Kurtz JE; Glasspool RM; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S83-9. PubMed ID: 25341586
[TBL] [Abstract][Full Text] [Related]
27. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
[TBL] [Abstract][Full Text] [Related]
28. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
29. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
30. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
31. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
32. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
33. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
34. Uterine papillary serous cancer: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Dec; 127(3):651-61. PubMed ID: 23000148
[TBL] [Abstract][Full Text] [Related]
35. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
36. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract][Full Text] [Related]
37. Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases.
Childs AJ; Burke JJ; Perry MY; Gallup DG
J Reprod Med; 2005 Mar; 50(3):209-12. PubMed ID: 15841935
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
Menderes G; Lopez S; Han C; Altwerger G; Gysler S; Varughese J; Schwartz PE; Santin AD
Discov Med; 2018 Aug; 26(141):39-50. PubMed ID: 30265854
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of uterine papillary serous carcinoma.
Roelofsen T; van Ham MA; de Hullu JA; Massuger LF
Expert Rev Anticancer Ther; 2011 Jan; 11(1):71-81. PubMed ID: 21166512
[TBL] [Abstract][Full Text] [Related]
40. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
